Your browser doesn't support javascript.
loading
Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests.
Rodgers, Mary A; Olivo, Ana; Harris, Barbara J; Lark, Chris; Luo, Xinxin; Berg, Michael G; Meyer, Todd V; Mohaimani, Aurash; Orf, Gregory S; Goldstein, Yitz; Fox, Amy S; Hirschhorn, Julie; Glen, William B; Nolte, Frederick; Landay, Alan; Jennings, Cheryl; Moy, James; Servellita, Venice; Chiu, Charles; Batra, Rahul; Snell, Luke B; Nebbia, Gaia; Douthwaite, Sam; Tanuri, Amilcar; Singh, Lavanya; de Oliveira, Tulio; Ahouidi, Ambroise; Mboup, Souleymane; Cloherty, Gavin A.
Afiliación
  • Rodgers MA; Abbott Diagnostics, Abbott Park, IL, USA. Electronic address: mary.rodgers@abbott.com.
  • Olivo A; Abbott Diagnostics, Abbott Park, IL, USA.
  • Harris BJ; Abbott Diagnostics, Abbott Park, IL, USA.
  • Lark C; Abbott Diagnostics, Abbott Park, IL, USA.
  • Luo X; Abbott Diagnostics, Abbott Park, IL, USA.
  • Berg MG; Abbott Diagnostics, Abbott Park, IL, USA.
  • Meyer TV; Abbott Diagnostics, Abbott Park, IL, USA.
  • Mohaimani A; Abbott Diagnostics, Abbott Park, IL, USA.
  • Orf GS; Abbott Diagnostics, Abbott Park, IL, USA.
  • Goldstein Y; Montefiore Medical Center, NY, USA.
  • Fox AS; Montefiore Medical Center, NY, USA.
  • Hirschhorn J; Medical University of South Carolina, SC, USA.
  • Glen WB; Medical University of South Carolina, SC, USA.
  • Nolte F; Medical University of South Carolina, SC, USA.
  • Landay A; Rush University Medical Center, IL, USA.
  • Jennings C; Rush University Medical Center, IL, USA.
  • Moy J; Rush University Medical Center, IL, USA.
  • Servellita V; University of California San Francisco, CA, USA.
  • Chiu C; University of California San Francisco, CA, USA.
  • Batra R; Guy's and St Thomas' NHS Foundation, London, UK.
  • Snell LB; Guy's and St Thomas' NHS Foundation, London, UK.
  • Nebbia G; Guy's and St Thomas' NHS Foundation, London, UK.
  • Douthwaite S; Guy's and St Thomas' NHS Foundation, London, UK.
  • Tanuri A; Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Singh L; University of KwaZulu-Natal, Durban, South Africa.
  • de Oliveira T; University of KwaZulu-Natal, Durban, South Africa.
  • Ahouidi A; Institute for Health Research Epidemiological Surveillance and Training, Dakar, Senegal.
  • Mboup S; Institute for Health Research Epidemiological Surveillance and Training, Dakar, Senegal.
  • Cloherty GA; Abbott Diagnostics, Abbott Park, IL, USA.
J Clin Virol ; 147: 105080, 2022 02.
Article en En | MEDLINE | ID: mdl-35086043
BACKGROUND: Viral diversity presents an ongoing challenge for diagnostic tests, which need to accurately detect all circulating variants. The Abbott Global Surveillance program monitors severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants and their impact on diagnostic test performance. OBJECTIVES: To evaluate the capacity of Abbott molecular, antigen, and serologic assays to detect circulating SARS-CoV-2 variants, including all current variants of concern (VOC): B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.2 (delta). STUDY DESIGN: Dilutions of variant virus cultures (B.1.1.7, B.1.351, B.1.429, B.1.526.1, B.1.526.2, B.1.617.1, B.1.617.2, P.1, R.1 and control isolate WA1) and a panel of N = 248 clinical samples from patients with sequence confirmed variant infections (B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.526, B.1.526.1, B.1.526.2, P.1, P.2, R.1) were evaluated on at least one assay: Abbott ID NOW COVID-19, m2000 RealTime SARS-CoV-2, Alinity m SARS-CoV-2, and Alinity m Resp-4-Plex molecular assays; the BinaxNOW COVID-19 Ag Card and Panbio COVID-19 Ag Rapid Test Device; and the ARCHITECT/Alinity i SARS-CoV-2 IgG and AdviseDx IgM assays, Panbio COVID-19 IgG assay, and ARCHITECT/Alinity i AdviseDx SARS-CoV-2 IgG II assay. RESULTS: Consistent with in silico predictions, each molecular and antigen assay detected VOC virus cultures with equivalent sensitivity to the WA1 control strain. Notably, 100% of all tested variant patient specimens were detected by molecular assays (N = 197 m2000, N = 88 Alinity m, N = 99 ID NOW), and lateral flow assays had a sensitivity of >94% for specimens with genome equivalents (GE) per device above 4 log (85/88, Panbio; 54/57 Binax). Furthermore, Abbott antibody assays detected IgG and IgM in 94-100% of sera from immune competent B.1.1.7 patients 15-26 days after symptom onset. CONCLUSIONS: These data confirm variant detection for 11 SARS-CoV-2 assays, which is consistent with each assay target region being highly conserved. Importantly, alpha, beta, gamma, and delta VOCs were detected by molecular and antigen assays, indicating that these tests may be suitable for widescale use where VOCs predominate.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: J Clin Virol Asunto de la revista: VIROLOGIA Año: 2022 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: J Clin Virol Asunto de la revista: VIROLOGIA Año: 2022 Tipo del documento: Article